What is the diagnostic workup and treatment for polycythemia?

Polycythemia: Diagnostic Workup and Treatment

For polycythemia vera (PV), maintain hematocrit strictly below 45% with phlebotomy and prescribe low-dose aspirin for all patients; add cytoreductive therapy with hydroxyurea or interferon-alpha for high-risk patients (age >60 years or prior thrombosis). 1

Diagnostic Workup

Initial Evaluation

Suspect PV when:

• Hemoglobin >18.5 g/dL (men) or >16.5 g/dL (women) 2
• Documented sustained increase in hemoglobin ≥2 g/dL from baseline 3
• Borderline-high hematocrit with PV-related features: thrombocytosis, leukocytosis, splenomegaly, aquagenic pruritus, unusual thrombosis (Budd-Chiari), or erythromelalgia 3

Diagnostic Algorithm

Step 1: Serum Erythropoietin (EPO) Level 3

• Low EPO: Highly suggestive of PV (>90% specificity)
• Normal EPO: PV still possible (sensitivity of low EPO only ~70%)
• High EPO: Evaluate for secondary polycythemia

Step 2: JAK2 Mutation Testing 2

• JAK2V617F mutation present in >95% of PV cases 4
• If negative, test for JAK2 exon 12 mutations
• Helps distinguish primary from secondary erythrocytosis

Step 3: Bone Marrow Biopsy 3, 5

Perform when diagnosis remains uncertain. Look for:

• Hypercellularity with trilineage proliferation (panmyelosis)
• Prominent erythroid, granulocytic, and megakaryocytic proliferation
• Increased megakaryocytes with cluster formation
• Decreased iron stores
• Mild reticulin fibrosis (grade 1) in 12% of cases

Diagnostic Criteria (WHO/ELN): 2, 5

PV diagnosis requires:

• Both major criteria + 1 minor criterion, OR
• First major criterion + 2 minor criteria

Major Criteria:

1. Hemoglobin >18.5 g/dL (men), >16.5 g/dL (women) OR hematocrit >49% (men), >48% (women)
2. JAK2V617F or JAK2 exon 12 mutation

Minor Criteria:

1. Bone marrow trilineage myeloproliferation
2. Subnormal serum EPO level
3. Endogenous erythroid colony growth

Exclude Secondary Causes

Rule out: tobacco smoking, sleep apnea, chronic lung disease, renal disease, high altitude, testosterone use, EPO-secreting tumors 4

Risk Stratification

Low Risk: Age <60 years AND no prior thrombosis 1, 6

High Risk: Age ≥60 years OR prior thrombotic event 1, 6

Additional thrombotic risk factors to address: dyslipidemia, hypertension, diabetes, smoking 6, 7

Treatment Strategy

All Patients (Universal Therapy)

1. Phlebotomy 1

• Target: Hematocrit <45% (Level I, Grade A evidence from CYTO-PV trial) 1
• This target significantly reduces thrombotic events compared to 45-50%
• Perform emergently if very high hematocrit with hyperviscosity symptoms
• Continue as maintenance therapy

2. Low-Dose Aspirin (75-100 mg daily) 1

• Level I, Grade A evidence from ECLAP study 1
• Reduces cardiovascular death, myocardial infarction, stroke, and venous thromboembolism
• Contraindications/Caution:
  • Platelet count >1000 × 10⁹/L (hemorrhage risk) 1
  • Acquired von Willebrand disease with extreme thrombocytosis (≥1000 × 10⁹/L) 4
  • Active bleeding or bleeding history

3. Cardiovascular Risk Factor Management 6

• Aggressively manage hypertension, diabetes, hyperlipidemia
• Mandatory smoking cessation

Low-Risk Patients

Continue phlebotomy and aspirin only 6, 3

High-Risk Patients (Age >60 or Prior Thrombosis)

Add cytoreductive therapy 1

First-Line Cytoreductive Options:

Hydroxyurea (HU) 1

• Level II, Grade A recommendation
• Starting dose: 500 mg twice daily orally 3
• Well-tolerated in most patients
• Use with caution in patients <40 years due to theoretical leukemogenic risk with prolonged exposure
• Monitor for: neutropenia, mucocutaneous changes, leg ulcers 3

Interferon-alpha (IFN-α) 1

• Level III, Grade B recommendation
• Preferred in younger patients (<40 years) and women of childbearing age 3
• Starting dose: 3 million units subcutaneously 3 times weekly 3
• Pegylated formulations available with improved tolerability
• Monitor for: flu-like symptoms, fatigue, depression, autoimmunity 3

Alternative agents in elderly (>70 years): Busulfan may be considered 6, 3

Additional Indications for Cytoreductive Therapy (Even in Low-Risk)

• Extreme thrombocytosis (>1500 × 10⁹/L) 1
• Progressive leukocytosis
• Symptomatic or progressive splenomegaly 6
• Severe disease-related symptoms
• Poor phlebotomy tolerance or frequent requirement 6

Second-Line Therapy

Ruxolitinib (JAK1/JAK2 inhibitor) 5, 4

• Recommended for patients intolerant of or with inadequate response to hydroxyurea
• Particularly effective for:
  • Intractable pruritus
  • Splenomegaly reduction
  • Constitutional symptoms

Criteria for HU resistance/intolerance: 1

• Need for phlebotomy after 3 months of ≥2 g/day HU to maintain hematocrit <45%
• Uncontrolled myeloproliferation (platelets >400 × 10⁹/L AND WBC >10 × 10⁹/L) after 3 months of ≥2 g/day HU
• Failure to reduce splenomegaly >50% after 3 months of ≥2 g/day HU
• Cytopenia at lowest effective HU dose
• Unacceptable HU toxicity (leg ulcers, mucocutaneous manifestations)

Follow-Up Monitoring

Frequency: 1

• Monthly until blood counts normalized
• Every 2 months once stable
• More frequent if symptomatic or on dose adjustments

At Each Visit:

• Complete blood count with differential
• Hematocrit monitoring (maintain <45%)
• Physical examination (splenomegaly assessment)
• Symptom assessment

Periodic Testing:

• Liver and renal function if on cytoreductive therapy
• Iron studies (iron deficiency common with phlebotomy)

Bone marrow biopsy: Only repeat if clinical signs of disease progression (myelofibrosis transformation, increasing splenomegaly, worsening cytopenias, increasing blasts) 1

Common Pitfalls

1. Don't target hematocrit 45-50%: The CYTO-PV trial definitively showed <45% is superior for thrombosis prevention 1

2. Don't withhold aspirin in stable thrombocytosis: Unless platelets >1000 × 10⁹/L or bleeding history 1

3. Don't delay cytoreductive therapy in high-risk patients: Age >60 or prior thrombosis mandates treatment beyond phlebotomy 1

4. Don't miss iron deficiency: Can mask true hemoglobin elevation; consider PV diagnosis even with "normal" hemoglobin if other features present and patient is iron deficient 2

5. Don't ignore cardiovascular risk factors: These significantly compound thrombotic risk 6, 7

Long-Term Complications

Monitor for:

• Thrombosis: 56% of patients experience thrombotic events (58% arterial, 42% venous) 7
• Myelofibrosis transformation: Occurs in 12.7% of patients 4
• Acute myeloid leukemia: Develops in 6.8% of patients 4
• Bleeding complications: Especially with extreme thrombocytosis

Median survival from diagnosis: 14-28 years across cohorts 4